{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T11:57:33Z","timestamp":1789387053222,"version":"build-2803163510"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"7580","license":[{"start":{"date-parts":[[2015,11,25]],"date-time":"2015-11-25T00:00:00Z","timestamp":1448409600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nature"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1038\/nature16159","type":"journal-article","created":{"date-parts":[[2015,11,25]],"date-time":"2015-11-25T05:21:10Z","timestamp":1448428870000},"page":"123-126","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":170,"title":["Reversal of phenotypes in MECP2 duplication mice using genetic rescue or antisense oligonucleotides"],"prefix":"10.1038","volume":"528","author":[{"given":"Yehezkel","family":"Sztainberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-mei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W.","family":"Swann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianrong","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Wooi","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhandong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Rigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huda Y.","family":"Zoghbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,11,25]]},"reference":[{"key":"BFnature16159_CR1","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1016\/j.cell.2012.02.039","volume":"148","author":"D Malhotra","year":"2012","unstructured":"Malhotra, D. & Sebat, J. CNVs: harbingers of a rare variant revolution in psychiatric genetics. Cell 148, 1223\u20131241 (2012)","journal-title":"Cell"},{"key":"BFnature16159_CR2","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1038\/ejhg.2008.208","volume":"17","author":"D Lugtenberg","year":"2009","unstructured":"Lugtenberg, D. et al. Structural variation in Xq28: MECP2 duplications in 1% of patients with unexplained XLMR and in 2% of male patients with severe encephalopathy. Eur. J. Hum. Genet. 17, 444\u2013453 (2009)","journal-title":"Eur. J. Hum. Genet."},{"key":"BFnature16159_CR3","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1159\/000329580","volume":"2","author":"H Van Esch","year":"2011","unstructured":"Van Esch, H. MECP2 duplication syndrome. Mol. Syndromol. 2, 128\u2013136 (2011)","journal-title":"Mol. Syndromol."},{"key":"BFnature16159_CR4","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1002\/ajmg.a.33184","volume":"152A","author":"MB Ramocki","year":"2010","unstructured":"Ramocki, M. B., Tavyev, Y. J. & Peters, S. U. The MECP2 duplication syndrome. Am. J. Med. Genet. A. 152A, 1079\u20131088 (2010)","journal-title":"Am. J. Med. Genet. A."},{"key":"BFnature16159_CR5","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1002\/(SICI)1096-8628(19990730)85:3<243::AID-AJMG11>3.0.CO;2-E","volume":"85","author":"H Lubs","year":"1999","unstructured":"Lubs, H. et al. XLMR syndrome characterized by multiple respiratory infections, hypertelorism, severe CNS deterioration and early death localizes to distal Xq28. Am. J. Med. Genet. 85, 243\u2013248 (1999)","journal-title":"Am. J. Med. Genet."},{"key":"BFnature16159_CR6","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/nature711","volume":"415","author":"RM Costa","year":"2002","unstructured":"Costa, R. M. et al. Mechanism for the learning deficits in a mouse model of neurofibromatosis type 1. Nature 415, 526\u2013530 (2002)","journal-title":"Nature"},{"key":"BFnature16159_CR7","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/nm1788","volume":"14","author":"D Ehninger","year":"2008","unstructured":"Ehninger, D. et al. Reversal of learning deficits in a Tsc2+\/\u2212 mouse model of tuberous sclerosis. Nature Med. 14, 843\u2013848 (2008)","journal-title":"Nature Med."},{"key":"BFnature16159_CR8","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/j.neuron.2007.12.001","volume":"56","author":"G D\u00f6len","year":"2007","unstructured":"D\u00f6len, G. et al. Correction of fragile X syndrome in mice. Neuron 56, 955\u2013962 (2007)","journal-title":"Neuron"},{"key":"BFnature16159_CR9","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1126\/science.1138389","volume":"315","author":"J Guy","year":"2007","unstructured":"Guy, J., Gan, J., Selfridge, J., Cobb, S. & Bird, A. Reversal of neurological defects in a mouse model of Rett syndrome. Science 315, 1143\u20131147 (2007)","journal-title":"Science"},{"key":"BFnature16159_CR10","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.molmed.2012.09.001","volume":"18","author":"AL Southwell","year":"2012","unstructured":"Southwell, A. L., Skotte, N. H., Bennett, C. F. & Hayden, M. R. Antisense oligonucleotide therapeutics for inherited neurodegenerative diseases. Trends Mol. Med. 18, 634\u2013643 (2012)","journal-title":"Trends Mol. Med."},{"key":"BFnature16159_CR11","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1146\/annurev.pharmtox.010909.105654","volume":"50","author":"CF Bennett","year":"2010","unstructured":"Bennett, C. F. & Swayze, E. E. RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu. Rev. Pharmacol. Toxicol. 50, 259\u2013293 (2010)","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"BFnature16159_CR12","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/nm.3106","volume":"19","author":"JJ Lentz","year":"2013","unstructured":"Lentz, J. J. et al. Rescue of hearing and vestibular function by antisense oligonucleotides in a mouse model of human deafness. Nature Med. 19, 345\u2013350 (2013)","journal-title":"Nature Med."},{"key":"BFnature16159_CR13","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/nature11362","volume":"488","author":"TM Wheeler","year":"2012","unstructured":"Wheeler, T. M. et al. Targeting nuclear RNA for in vivo correction of myotonic dystrophy. Nature 488, 111\u2013115 (2012)","journal-title":"Nature"},{"key":"BFnature16159_CR14","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/nature10485","volume":"478","author":"Y Hua","year":"2011","unstructured":"Hua, Y. et al. Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model. Nature 478, 123\u2013126 (2011)","journal-title":"Nature"},{"key":"BFnature16159_CR15","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/nature13975","volume":"518","author":"L Meng","year":"2015","unstructured":"Meng, L. et al. Towards a therapy for Angelman syndrome by targeting a long non-coding RNA. Nature 518, 409\u2013412 (2015)","journal-title":"Nature"},{"key":"BFnature16159_CR16","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/j.neuron.2012.05.009","volume":"74","author":"HB Kordasiewicz","year":"2012","unstructured":"Kordasiewicz, H. B. et al. Sustained therapeutic reversal of Huntington\u2019s disease by transient repression of huntingtin synthesis. Neuron 74, 1031\u20131044 (2012)","journal-title":"Neuron"},{"key":"BFnature16159_CR17","doi-asserted-by":"publisher","first-page":"72ra18","DOI":"10.1126\/scitranslmed.3001777","volume":"3","author":"MA Passini","year":"2011","unstructured":"Passini, M. A. et al. Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy. Sci. Transl. Med. 3, 72ra18 (2011)","journal-title":"Sci. Transl. Med."},{"key":"BFnature16159_CR18","doi-asserted-by":"publisher","first-page":"2290","DOI":"10.1172\/JCI25424","volume":"116","author":"RA Smith","year":"2006","unstructured":"Smith, R. A. et al. Antisense oligonucleotide therapy for neurodegenerative disease. J. Clin. Invest. 116, 2290\u20132296 (2006)","journal-title":"J. Clin. Invest."},{"key":"BFnature16159_CR19","doi-asserted-by":"publisher","first-page":"2679","DOI":"10.1093\/hmg\/ddh282","volume":"13","author":"AL Collins","year":"2004","unstructured":"Collins, A. L. et al. Mild overexpression of MeCP2 causes a progressive neurological disorder in mice. Hum. Mol. Genet. 13, 2679\u20132689 (2004)","journal-title":"Hum. Mol. Genet."},{"key":"BFnature16159_CR20","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/ng.1066","volume":"44","author":"RC Samaco","year":"2012","unstructured":"Samaco, R. C. et al. Crh and Oprm1 mediate anxiety-related behavior and social approach in a mouse model of MECP2 duplication syndrome. Nature Genet. 44, 206\u2013211 (2012)","journal-title":"Nature Genet."},{"key":"BFnature16159_CR21","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1126\/science.1153252","volume":"320","author":"M Chahrour","year":"2008","unstructured":"Chahrour, M. et al. MeCP2, a key contributor to neurological disease, activates and represses transcription. Science 320, 1224\u20131229 (2008)","journal-title":"Science"},{"key":"BFnature16159_CR22","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1093\/hmg\/ddp181","volume":"18","author":"S Ben-Shachar","year":"2009","unstructured":"Ben-Shachar, S., Chahrour, M., Thaller, C., Shaw, C. A. & Zoghbi, H. Y. Mouse models of MeCP2 disorders share gene expression changes in the cerebellum and hypothalamus. Hum. Mol. Genet. 18, 2431\u20132442 (2009)","journal-title":"Hum. Mol. Genet."},{"key":"BFnature16159_CR23","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/nature09582","volume":"468","author":"HT Chao","year":"2010","unstructured":"Chao, H. T. et al. Dysfunction in GABA signalling mediates autism-like stereotypies and Rett syndrome phenotypes. Nature 468, 263\u2013269 (2010)","journal-title":"Nature"},{"key":"BFnature16159_CR24","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/0092-8674(92)90610-O","volume":"69","author":"JD Lewis","year":"1992","unstructured":"Lewis, J. D. et al. Purification, sequence, and cellular localization of a novel chromosomal protein that binds to methylated DNA. Cell 69, 905\u2013914 (1992)","journal-title":"Cell"},{"key":"BFnature16159_CR25","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/30764","volume":"393","author":"X Nan","year":"1998","unstructured":"Nan, X. et al. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 393, 386\u2013389 (1998)","journal-title":"Nature"},{"key":"BFnature16159_CR26","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/561","volume":"19","author":"PL Jones","year":"1998","unstructured":"Jones, P. L. et al. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nature Genet. 19, 187\u2013191 (1998)","journal-title":"Nature Genet."},{"key":"BFnature16159_CR27","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/nn.3027","volume":"15","author":"HT Chao","year":"2012","unstructured":"Chao, H. T. & Zoghbi, H. Y. MeCP2: only 100% will do. Nature Neurosci. 15, 176\u2013177 (2012)","journal-title":"Nature Neurosci."},{"key":"BFnature16159_CR28","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/ng0692-159","volume":"1","author":"PI Patel","year":"1992","unstructured":"Patel, P. I. et al. The gene for the peripheral myelin protein PMP-22 is a candidate for Charcot-Marie-Tooth disease type 1A. Nature Genet. 1, 159\u2013165 (1992)","journal-title":"Nature Genet."},{"key":"BFnature16159_CR29","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1086\/512864","volume":"80","author":"L Potocki","year":"2007","unstructured":"Potocki, L. et al. Characterization of Potocki-Lupski syndrome (dup(17)(p11.2p11.2)) and delineation of a dosage-sensitive critical interval that can convey an autism phenotype. Am. J. Hum. Genet. 80, 633\u2013649 (2007)","journal-title":"Am. J. Hum. Genet."},{"key":"BFnature16159_CR30","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/nature04678","volume":"441","author":"JR Arron","year":"2006","unstructured":"Arron, J. R. et al. NFAT dysregulation by increased dosage of DSCR1 and DYRK1A on chromosome 21. Nature 441, 595\u2013600 (2006)","journal-title":"Nature"},{"key":"BFnature16159_CR31","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1037\/0735-7044.115.2.468","volume":"115","author":"MN Cook","year":"2001","unstructured":"Cook, M. N., Williams, R. W. & Flaherty, L. Anxiety-related behaviors in the elevated zero-maze are affected by genetic factors and retinal degeneration. Behav. Neurosci. 115, 468\u2013476 (2001)","journal-title":"Behav. Neurosci."},{"key":"BFnature16159_CR32","doi-asserted-by":"publisher","first-page":"R36","DOI":"10.1186\/gb-2013-14-4-r36","volume":"14","author":"D Kim","year":"2013","unstructured":"Kim, D. et al. TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol. 14, R36 (2013)","journal-title":"Genome Biol."},{"key":"BFnature16159_CR33","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1093\/bioinformatics\/btu638","volume":"31","author":"S Anders","year":"2015","unstructured":"Anders, S., Pyl, P. T. & Huber, W. HTSeq\u2013a Python framework to work with high-throughput sequencing data. Bioinformatics 31, 166\u2013169 (2015)","journal-title":"Bioinformatics"},{"key":"BFnature16159_CR34","doi-asserted-by":"publisher","first-page":"R106","DOI":"10.1186\/gb-2010-11-10-r106","volume":"11","author":"S Anders","year":"2010","unstructured":"Anders, S. & Huber, W. Differential expression analysis for sequence count data. Genome Biol. 11, R106 (2010)","journal-title":"Genome Biol."},{"key":"BFnature16159_CR35","unstructured":"Paxinos, G. & Franklin, K. B. The Mouse Brain in Stereotaxic Coordinates (Academic, 2001)"},{"key":"BFnature16159_CR36","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/nature12630","volume":"503","author":"K Han","year":"2013","unstructured":"Han, K. et al. SHANK3 overexpression causes manic-like behaviour with unique pharmacogenetic properties. Nature 503, 72\u201377 (2013)","journal-title":"Nature"},{"key":"BFnature16159_CR37","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1523\/JNEUROSCI.4152-10.2011","volume":"31","author":"ED Roberson","year":"2011","unstructured":"Roberson, E. D. et al. Amyloid-\u03b2\/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer\u2019s disease. J. Neurosci. 31, 700\u2013711 (2011)","journal-title":"J. Neurosci."}],"container-title":["Nature"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nature16159.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nature16159","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nature16159.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,15]],"date-time":"2023-08-15T19:40:39Z","timestamp":1692128439000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nature16159"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,25]]},"references-count":37,"journal-issue":{"issue":"7580","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["BFnature16159"],"URL":"https:\/\/doi.org\/10.1038\/nature16159","relation":{},"ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,25]]},"assertion":[{"value":"24 December 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"F.R. is an employee of Isis Pharamaceuticals.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}